By Mark G. Edwards
As a licensing professional in the biopharma industry for the past three decades, I’d argue that there is no component of a biopharma contract that is more heavily relied upon, and less rigorously analyzed, than the royalty rate.
Full articles are available only to LESI Members. Please login to view the PDF of this Les Nouvelles Article.
Not an LESI member? Find out how to join your regional LES society and gain access to all that your LES society and LESI has to offer.